Efficacy of concurrent radio-chemotherapy and chemotherapy alone in the treatment of locally advanced non-small-cell lung cancer.
- Author:
Hua WU
1
;
Zhong XIE
;
Zhen-nan WANG
;
Li-ping FENG
;
Zhi-xiong YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; radiotherapy; Cisplatin; administration & dosage; Combined Modality Therapy; Female; Humans; Lung Neoplasms; drug therapy; radiotherapy; Male; Middle Aged; Radiation-Sensitizing Agents; administration & dosage; Vinblastine; administration & dosage; analogs & derivatives
- From: Chinese Journal of Oncology 2005;27(8):502-504
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect and acute toxicity of concurrent radio-chemotherapy, by NVB and DDP, plus concurrent radiotherapy in comparison with chemotherapy alone in the treatment of inoperable locally advanced non-small-cell lung cancer (LANSCLC).
METHODSSixty-four patients with inoperable LANSCLC were randomly divided by envelope method into two groups: concurrent radio-chemotherapy group (n = 33) and conventional chemotherapy group (n = 31). The patients in conventional chemotherapy group were treated by NP regimen (NVB + DDP): NVB 25 mg/m(2), d1, 8 and DDP 25-30 mg/m(2) d1-3. In the radio-chemotherapy group by NP regimen plus conventional radiotherapy by (60)Co: 64-68 Gy/2 Gy x 5/w x 6-7w.
RESULTSAll patients completed the treatment schedule. The overall response rate (CR + PR) in the radio-chemotherapy group was significantly higher than that in the conventional chemotherapy group: 81.8% vs 45.2%, (P < 0.01) with 1- and 2-year survival rates of 69.7% vs 38.7% (P < 0.05) and 39.4% vs 16.1% (P < 0.05). without any significant difference in the acute toxicity between two groups (P > 0.05).
CONCLUSIONCompared with conventional chemotherapy (NVP and DDP), concurrent radio-chemotherapy (NVP and DDP plus concurrent radiotherapy) is more effective and tolerable for the inoperable locally advanced non-small-cell lung cancer.
